XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS’ EQUITY
 9 Months Ended
Sep. 27, 2024
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
Share-based Compensation Plans
The following table sets forth the detailed allocation of the share-based compensation expense which was included in the Company’s condensed consolidated statements of operations:
 Three Months EndedNine Months Ended
(in thousands)September 27, 2024September 29, 2023September 27, 2024September 29, 2023
Cost of revenue$295 $606 $1,091 $1,895 
Research and development expense1,804 2,152 5,282 5,982 
Selling, general and administrative expense3,611 4,483 13,214 12,847 
Total$5,710 $7,241 $19,587 $20,724 
Restricted Stock Units:
(in thousands, except per share amounts)Number
of
Shares		Weighted Average
Grant-Date Fair Value
Per Share
Balance at December 31, 20233,242 $12.42 
Granted3,128 13.22
Vested(1,831)12.07
Forfeited(848)13.96
Balance at September 27, 20243,691 $12.92 
The Company’s stock benefit plans include the 2002 Employee Stock Purchase Plan (as amended and restated, the “ESPP”) and current active stock plans adopted in 1995 and 2002 (as amended and restated, the “1995 Stock Plan” and “2002 Director Plan”, respectively). Refer to Note 12, “Employee Benefit Plans” of Notes to Consolidated Financial Statements in the 2023 Form 10-K for details pertaining to each plan.
At the Company’s 2024 annual meeting, the Company’s stockholders approved amendments to the 1995 Stock Plan and the 2002 ESPP, increasing the number of shares of common stock reserved for issuance by 5,000,000 shares and 400,000 shares, respectively. As of September 27, 2024, an aggregate of 6,756,857 shares of common stock were reserved for issuance under the 1995 Stock Plan, of which 2,756,049 shares remained available for future grants. As of September 27, 2024, an aggregate of 588,191 shares of common stock were reserved for issuance under the 2002 Director Plan, of which 374,341 shares remained available for future grants.
Share Repurchase Program
In February 2022, the Board of Directors of the Company (“Board”) authorized the Company to repurchase up to $100 million of the Company’s outstanding shares of common stock through February 2025. The Company is authorized to repurchase, from time-to-time, shares of its outstanding common stock through open market purchases and 10b5-1 trading plans, in accordance with applicable rules and regulations, at such time and such prices as management may decide. The program does not obligate the Company to repurchase any specific number of shares and may be discontinued at any time. The actual timing and amount of repurchases are subject to business and market conditions, corporate and regulatory requirements, stock price, acquisition opportunities and other factors.
During the nine months ended September 27, 2024, the Company repurchased and retired approximately 2.4 million shares of the Company’s common stock for an aggregate amount of $30.0 million. As of September 27, 2024, approximately $64.8 million of the share repurchase authorization remained available for repurchases under this program.